EXHIBIT 83

```
1
              UNITED STATES DISTRICT COURT
            FOR THE NORTHERN DISTRICT OF OHIO
 2
                    EASTERN DIVISION
 3
       IN RE: NATIONAL
 4
      PRESCRIPTION
                                MDL No. 2804
                             )
       OPIATE LITIGATION
 5
                             ) Case No.
                                 1:17-MD-2804
 6
       THIS DOCUMENT RELATES ) Hon. Dan A.
 7
                             ) Polster
       TO ALL CASES
 8
                TUESDAY, JANUARY 15, 2019
 9
        HIGHLY CONFIDENTIAL - SUBJECT TO FURTHER
10
                 CONFIDENTIALITY REVIEW
11
12
                Videotaped deposition of Karen
13
      Harper, held at the offices of STINSON
14
      LEONARD STREET LLP, 7700 Forsyth Boulevard,
15
      Suite 1000, St. Louis, Missouri, commencing
      at 9:09 a.m., on the above date, before
16
17
      Carrie A. Campbell, Registered Diplomate
18
     Reporter and Certified Realtime Reporter.
19
20
21
22
               GOLKOW LITIGATION SERVICES
23
          877.370.3377 ph | 917.591.5672 fax
                     deps@golkow.com
24
25
```

	<u> </u>		
	Page 30		Page 32
1	Q. Okay. Do you have an 09:23:54	1	3 · · · ·
2	approximate recollection of how much you 09:23:55	2	A. It's percent. 09:25:20
3	made? 09:23:57	3	Q. Okay. And has that over the 09:25:23
4	A. No, sir. 09:23:57	4	time that you've either been senior manager 09:25:27
5	Q. Okay. Do you recall if it was 09:23:59	5	or director of controlled substance 09:25:28
6	\$75,000 or more or above? 09:24:01	6	compliance, has it been that approximate 09:25:30
7	A. No, sir, I don't recall. 09:24:03	7	percentage? 09:25:32
8	Q. Okay. Do you know what your 09:24:04	8	A. Yes. 09:25:32
9	salary is currently? 09:24:09	9	Q. Okay. Great. 09:25:34
10	A. Yes. 09:24:10	10	Ms. Harper, have you reviewed 09:25:35
11	Q. Okay. And you're currently 09:24:13	11	any court documents or pleadings in this 09:25:39
12	director of controlled substance compliance, 09:24:15	12	case? 09:25:42
13	correct? 09:24:18	13	A. I'm not certain. 09:25:42
14	A. Yes. 09:24:19	14	Q. Okay. Are you aware that 09:25:46
15	Q. And what is your salary 09:24:19	15	there's a case currently pending in Ohio, 09:25:49
16	currently? 09:24:21	16	generally titled the national opioid 09:25:54
17	A. It's I'm going to give you 09:24:21	17	litigation? 09:25:56
18	two numbers because I get that mixed up as 09:24:24	18	A. Yes. 09:25:56
19	well, I'm sorry. It's either or 09:24:27	19	Q. And you're aware that there are 09:25:57
20	per year. 09:24:31	20	approximately 1500 jurisdictions that have 09:25:58
21	Q. 09:24:32	21	filed suit against various manufacturers, 09:26:02
22	A. 09:24:34	22	distributors and retail pharmacies of 09:26:07
23	Q. 09:24:35	23	prescription opioids? 09:26:08
24	09:24:39	24	A. Yes. 09:26:08
25	A. 09:24:40	25	Q. Okay. And are you aware that 09:26:08
	Page 31		Page 33
1	. 09:24:42	1	these jurisdictions have alleged that these 09:26:09
2	Q. And when did you start 09:24:42	2	entities are responsible for the opioid 09:26:12
3	09:24:44	3	crisis? 09:26:14
4	A. I don't recall the year. 09:24:44	4	A. Yes. 09:26:15
5	Q. Okay. And do you have any 09:24:45	5	Q. Okay. By the way, are you 09:26:16
6	other do you have a retirement package at 09:24:49	6	aware strike that. 09:26:20
7	all? 09:24:51	7	Are you generally aware that 09:26:20
8	A. Yes. 09:24:52	8	these jurisdictions are alleging that these 09:26:25
9	Q. Okay. And what does that 09:24:53	9	entities should be responsible for the costs 09:26:28
10	consist of? 09:24:54	10	that these entities have incurred as a result 09:26:30
11	A. It's 401(k). 09:24:55	11	of responding to the opioid crisis? 09:26:33
12	Q. Okay. Other than the 401(k) 09:24:56	12	A. Yes, in general. 09:26:35
13	and , do you 09:24:58	13	Q. Okay. And are you aware of any 09:26:36
14	have any other additional compensation in 09:25:01	14	complaints that have actually been filed 09:26:39
15	addition to your salary? 09:25:04	15	against your company? 09:26:42
16	A. Yes. 09:25:05	16	A. No. 09:26:43
17	Q. And what does that consist of? 09:25:07	17	Q. Okay. So you haven't read any 09:26:46
18	A. A bonus, an annual bonus. 09:25:08	18	of the complaints that have been filed 09:26:47
19	Q. Okay. And approximately how 09:25:10	19	against Mallinckrodt? 09:26:50
20	much is that? 09:25:11	20	A. I've read pieces of the MDL, 09:26:51
21	A. It's it's a percent of the 09:25:11	21	but nothing specific to Mallinckrodt. 09:26:55
22	salary based upon the performance of the 09:25:14	22	Q. Okay. When you say "pieces of 09:26:56
23	company. 09:25:17	23	the MDL," what do you mean? 09:26:59
23	company. 09:25:17 Q. Okay. And what's the 09:25:17	24	A. The multi-district litigation. 09:27:01
	company. 09:25:17		•

	Page 34		Page 36
1	"pieces," I'm just trying to get an 09:27:04	1	THE WITNESS: That is not 09:28:44
2	understanding of what you've reviewed. 09:27:06	2	the sta pardon me, the statistic I 09:28:46
3	A. So we receive a pharma news 09:27:07	3	have heard. 09:28:48
4	brief every single day, and so there will be 09:27:10	4	QUESTIONS BY MR. KO: 09:28:48
5	excerpts from the various matters related to 09:27:13	5	Q. Okay. What is the statistic 09:28:49
6	the MDL, Judge Polster's rulings, et cetera. 09:27:16	6	that you have heard? 09:28:50
7	Q. I see. 09:27:20	7	A. That we're in the top five 09:28:50
8	So in other words, you're 09:27:20	8	Q. Okay. 09:28:50
9	getting and receiving and reviewing these 09:27:22	9	A of the share of generic 09:28:53
10	news updates about the MDL? 09:27:26	10	suppliers. 09:28:55
11	A. Correct. 09:27:28	11	Q. Okay. And generic suppliers of 09:28:55
12	Q. Okay. Great. 09:27:29	12	prescription opioids in particular, correct? 09:28:58
13	Ms. Harper, do you agree that 09:27:30	13	A. Yes. 09:28:59
14	there's an opioid epidemic in this country? 09:27:35	14	Q. Okay. And currently, do you 09:29:00
15	MR. O'CONNOR: Object to form. 09:27:37	15	understand that Mallinckrodt has the number 09:29:05
16	THE WITNESS: Yes, I do. 09:27:38	16	one market share of generic prescription 09:29:07
17	QUESTIONS BY MR. KO: 09:27:39	17	opioids? 09:29:10
18	Q. Okay. And are you aware that 09:27:41	18	MR. O'CONNOR: Object to form. 09:29:10
19	there's been an opioid epidemic in this 09:27:43	19	THE WITNESS: I don't I'm 09:29:11
20	country for quite some time? 09:27:45	20	sorry. I don't know. I don't know 09:29:12
21	MR. O'CONNOR: Object to form. 09:27:47	21	our current market position. 09:29:13
22	THE WITNESS: I don't know, 09:27:47	22	QUESTIONS BY MR. KO: 09:29:14
23	sir, what you mean by "quite some 09:27:50	23	Q. Okay. During your time as 09:29:14
24	time." 09:27:51	24	director or senior manager of controlled 09:29:18
25	Can you I don't know. 09:27:52	25	substance compliance, have you ever inquired 09:29:21
23	Can you I don't know. 09.27.32	23	substance compnance, have you ever inquired 09.29.21
	Page 35		Page 37
1	Page 35 QUESTIONS BY MR. KO: 09:27:53	1	Page 37 as to the market share of Mallinckrodt with 09:29:23
1 2	_	1 2	- 1
	QUESTIONS BY MR. KO: 09:27:53		as to the market share of Mallinckrodt with 09:29:23
2	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54	2	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26
2 3	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic 09:27:57	2	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28
2 3 4	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic 09:27:57 in this country? 09:28:02	2 3 4	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31
2 3 4 5	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic 09:27:57 in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03	2 3 4 5	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32
2 3 4 5 6	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic 09:27:57 in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04	2 3 4 5 6	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34
2 3 4 5 6 7	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic op:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately op:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06	2 3 4 5 6 7	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40
2 3 4 5 6 7 8	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic op:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately op:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06	2 3 4 5 6 7 8	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43
2 3 4 5 6 7 8	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic 09:27:57 in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08	2 3 4 5 6 7 8	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40
2 3 4 5 6 7 8 9	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic 09:27:57 in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08	2 3 4 5 6 7 8 9	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46
2 3 4 5 6 7 8 9 10	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic 09:27:57 in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription 09:28:10	2 3 4 5 6 7 8 9 10	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51
2 3 4 5 6 7 8 9 10 11	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic 09:27:57 in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Malling trod's market share of prescription 09:28:10 opioids? 09:28:13	2 3 4 5 6 7 8 9 10 11 12	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52
2 3 4 5 6 7 8 9 10 11 12 13	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic o9:27:57 in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription 09:28:10 opioids? 09:28:13 A. On some products, yes. 09:28:13	2 3 4 5 6 7 8 9 10 11 12 13 14	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57
2 3 4 5 6 7 8 9 10 11 12 13	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with op:28:08 Mallinckrodt's market share of prescription opioids? 09:28:13 A. On some products, yes. 09:28:13 A. On some products, yes. 09:28:18	2 3 4 5 6 7 8 9 10 11 12 13 14	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57 Has that been inquiries that 09:30:03
2 3 4 5 6 7 8 9 10 11 12 13 14 15	QUESTIONS BY MR. KO: 09:27:53 Q. When did you first start 09:27:54 believing that there was an opioid epidemic o9:27:57 in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription 09:28:10 opioids? 09:28:13 A. On some products, yes. 09:28:13 Q. Okay. With respect to the 09:28:18 generic product line of Mallinckrodt, are you 09:28:20	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57 Has that been inquiries that 09:30:03 you've made on a fairly regular basis? 09:30:04
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	QUESTIONS BY MR. KO: Q. When did you first start 09:27:54 believing that there was an opioid epidemic o9:27:57 in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription 09:28:10 opioids? 09:28:13 A. On some products, yes. 09:28:13 Q. Okay. With respect to the 09:28:18 generic product line of Mallinckrodt, are you 09:28:20 aware of Mallinckrodt's market share in the 09:28:24	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57 Has that been inquiries that 09:30:03 you've made on a fairly regular basis? 09:30:04 MR. O'CONNOR: Object to form. 09:30:07
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	QUESTIONS BY MR. KO: Q. When did you first start 09:27:54 believing that there was an opioid epidemic o9:27:57 in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription opioids? 09:28:13 A. On some products, yes. 09:28:13 Q. Okay. With respect to the 09:28:18 generic product line of Mallinckrodt, are you 09:28:24 generic line of business? 09:28:27	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57 Has that been inquiries that 09:30:03 you've made on a fairly regular basis? 09:30:04 MR. O'CONNOR: Object to form. 09:30:07 THE WITNESS: Yes, in 09:30:07
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	QUESTIONS BY MR. KO: Q. When did you first start 09:27:54 believing that there was an opioid epidemic in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription 09:28:10 opioids? 09:28:13 A. On some products, yes. 09:28:13 Q. Okay. With respect to the 09:28:18 generic product line of Mallinckrodt, are you 09:28:20 aware of Mallinckrodt's market share in the 09:28:24 generic line of business? 09:28:27 A. Not overall, no, sir. 09:28:29	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57 Has that been inquiries that 09:30:03 you've made on a fairly regular basis? 09:30:04 MR. O'CONNOR: Object to form. 09:30:07 THE WITNESS: Yes, in 09:30:07 coordination with quota requests to 09:30:08
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	QUESTIONS BY MR. KO: Q. When did you first start 09:27:54 believing that there was an opioid epidemic in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription 09:28:10 opioids? 09:28:13 A. On some products, yes. 09:28:13 Q. Okay. With respect to the 09:28:18 generic product line of Mallinckrodt, are you 09:28:20 aware of Mallinckrodt's market share in the 09:28:24 generic line of business? 09:28:27 A. Not overall, no, sir. 09:28:29 Q. Okay. Are you aware that 09:28:31	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57 Has that been inquiries that 09:30:03 you've made on a fairly regular basis? 09:30:04 MR. O'CONNOR: Object to form. 09:30:07 THE WITNESS: Yes, in 09:30:07 coordination with quota requests to 09:30:08 DEA, yes. 09:30:09
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	QUESTIONS BY MR. KO: Q. When did you first start 09:27:54 believing that there was an opioid epidemic in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription opioids? 09:28:13 A. On some products, yes. 09:28:13 Q. Okay. With respect to the 09:28:18 generic product line of Mallinckrodt, are you op:28:20 aware of Mallinckrodt's market share in the 09:28:24 generic line of business? 09:28:27 A. Not overall, no, sir. 09:28:29 Q. Okay. Are you aware that 09:28:31 Mallinckrodt has been either the number one 09:28:34	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57 Has that been inquiries that 09:30:03 you've made on a fairly regular basis? 09:30:04 MR. O'CONNOR: Object to form. 09:30:07 THE WITNESS: Yes, in 09:30:07 coordination with quota requests to 09:30:08 DEA, yes. 09:30:09 QUESTIONS BY MR. KO: 09:30:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	QUESTIONS BY MR. KO: Q. When did you first start 09:27:54 believing that there was an opioid epidemic in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription opioids? 09:28:13 A. On some products, yes. 09:28:13 Q. Okay. With respect to the 09:28:18 generic product line of Mallinckrodt, are you op:28:20 aware of Mallinckrodt's market share in the 09:28:24 generic line of business? 09:28:27 A. Not overall, no, sir. 09:28:29 Q. Okay. Are you aware that 09:28:31 Mallinckrodt has been either the number one 09:28:34 or number two in terms of market share 09:28:36	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57 Has that been inquiries that 09:30:03 you've made on a fairly regular basis? 09:30:04 MR. O'CONNOR: Object to form. 09:30:07 THE WITNESS: Yes, in 09:30:07 coordination with quota requests to 09:30:08 DEA, yes. 09:30:09 QUESTIONS BY MR. KO: 09:30:10 Q. And those quota requests on an 09:30:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	QUESTIONS BY MR. KO: Q. When did you first start 09:27:54 believing that there was an opioid epidemic in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription 09:28:10 opioids? 09:28:13 A. On some products, yes. 09:28:13 Q. Okay. With respect to the 09:28:18 generic product line of Mallinckrodt, are you 09:28:20 aware of Mallinckrodt's market share in the 09:28:24 generic line of business? 09:28:27 A. Not overall, no, sir. 09:28:29 Q. Okay. Are you aware that 09:28:31 Mallinckrodt has been either the number one 09:28:34 or number two in terms of market share 09:28:36 generic manufacturer of prescription opioids 09:28:40	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57 Has that been inquiries that 09:30:03 you've made on a fairly regular basis? 09:30:04 MR. O'CONNOR: Object to form. 09:30:07 THE WITNESS: Yes, in 09:30:07 coordination with quota requests to 09:30:08 DEA, yes. 09:30:09 QUESTIONS BY MR. KO: 09:30:10 annual basis, correct? 09:30:13
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	QUESTIONS BY MR. KO: Q. When did you first start 09:27:54 believing that there was an opioid epidemic in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription opioids? 09:28:13 A. On some products, yes. 09:28:13 Q. Okay. With respect to the 09:28:18 generic product line of Mallinckrodt, are you op:28:24 generic line of business? 09:28:27 A. Not overall, no, sir. 09:28:29 Q. Okay. Are you aware that 09:28:34 or number two in terms of market share 09:28:36 generic manufacturer of prescription opioids 09:28:40 for the last 20 or so years? 09:28:42	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57 Has that been inquiries that 09:30:03 you've made on a fairly regular basis? 09:30:04 MR. O'CONNOR: Object to form. 09:30:07 THE WITNESS: Yes, in 09:30:07 coordination with quota requests to 09:30:08 DEA, yes. 09:30:09 QUESTIONS BY MR. KO: 09:30:10 annual basis, correct? 09:30:13 A. Quota is granted on an annual 09:30:13
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	QUESTIONS BY MR. KO: Q. When did you first start 09:27:54 believing that there was an opioid epidemic in this country? 09:28:02 MR. O'CONNOR: Object to form. 09:28:03 THE WITNESS: Approximately 09:28:04 mid-2000s. 09:28:05 QUESTIONS BY MR. KO: 09:28:06 Q. Mid-2000s? 09:28:07 A. Yes, sir. 09:28:08 Q. Okay. Are you familiar with 09:28:08 Mallinckrodt's market share of prescription 09:28:10 opioids? 09:28:13 A. On some products, yes. 09:28:13 Q. Okay. With respect to the 09:28:18 generic product line of Mallinckrodt, are you 09:28:20 aware of Mallinckrodt's market share in the 09:28:24 generic line of business? 09:28:27 A. Not overall, no, sir. 09:28:29 Q. Okay. Are you aware that 09:28:31 Mallinckrodt has been either the number one 09:28:34 or number two in terms of market share 09:28:36 generic manufacturer of prescription opioids 09:28:40	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	as to the market share of Mallinckrodt with 09:29:23 respect to prescription opioids? 09:29:26 A. On certain specific drug 09:29:28 substances, yes. 09:29:31 Q. And which specific drug 09:29:32 substances? 09:29:34 A. So I'll use the example 09:29:34 methylphenidate. When we're applying for 09:29:40 quota, if there is an intent or if we have a 09:29:43 belief that we will grow our market share, I 09:29:46 need to learn the existing market share that 09:29:48 Mallinckrodt holds. 09:29:51 Q. Okay. And when over the last 09:29:52 20 or so years have you inquired into that? 09:29:57 Has that been inquiries that 09:30:03 you've made on a fairly regular basis? 09:30:04 MR. O'CONNOR: Object to form. 09:30:07 THE WITNESS: Yes, in 09:30:07 coordination with quota requests to 09:30:08 DEA, yes. 09:30:09 QUESTIONS BY MR. KO: 09:30:10 annual basis, correct? 09:30:13

	P 20	_	
1	Page 38 process throughout a calendar year. 09:30:19	1	Page 40 Q. And who reports to you? 09:31:57
1 2		1	• •
	Q. Okay. And so you would say 09:30:20 that you have regularly I just want to 09:30:22	2	A. I have two direct reports. 09:31:58 They are managers of controlled substances 09:32:01
3		3	
4	make sure I understand when you when you 09:30:25	4	r
5	have inquired into understanding 09:30:28	5	Q. And who are they? 09:32:07
6	Mallinckrodt's market share, and you've said 09:30:30	6	A. There's a gentleman named 09:32:07
7	on a fairly consistent basis, correct? 09:30:32	7	his name is Dave Hunter. 09:32:10
8	A. Yes. 09:30:34	8	Q. And who is the other person? 09:32:14
9	Q. Okay. And consistent means 09:30:36	9	You said there were two? 09:32:17
10	throughout the year, as you've described, in 09:30:40	10	A. Eileen Spaulding. 09:32:17
11	connection with issues when dealing with 09:30:42	11	Q. Okay. And you have worked with 09:32:19
12	quota requests to the DEA? 09:30:45	12	Mr. Hunter and Ms. Spaulding before, correct? 09:32:21
13	MR. O'CONNOR: Object to form. 09:30:47	13	A. Correct. 09:32:24
14	THE WITNESS: Yes, throughout 09:30:47	14	Q. And you worked with them in 09:32:25
15	the year, but on certain drug 09:30:49	15	connection with the controlled substance 09:32:26
16	substances at different times, sir. 09:30:51	16	compliance team throughout the time you were 09:32:30
17	QUESTIONS BY MR. KO: 09:30:52	17	senior manager, correct? 09:32:31
18	Q. Okay. Going back to your 09:30:53	18	A. Correct. 09:32:32
19	current position as director of controlled 09:30:57	19	(Mallinckrodt-Harper Exhibit 1 09:32:40
20	substance compliance 09:31:01	20	marked for identification.) 09:32:40
21	A. Sorry. 09:31:02	21	QUESTIONS BY MR. KO: 09:32:40
22	Q. That's okay. 09:31:03	22	Q. I'd like to hand you an 09:32:41
23	when did you become 09:31:05	23	exhibit. Go ahead and mark this as Harper 09:32:42
24	director? 09:31:07	24	Exhibit 1. 09:32:56
25	A. Within the last six months. 09:31:08	25	And there's no Bates on this, 09:33:09
	Page 39		Page 41
1	O. Okay. So fairly recently? 09:31:11	1	Page 41 but this this appears to be a printout of 09:33:12
1 2	Q. Okay. So fairly recently? 09:31:11	1 2	but this this appears to be a printout of 09:33:12
1 2 3	Q. Okay. So fairly recently? 09:31:11A. Yes, sir. 09:31:12	1 2 3	_
2 3	Q. Okay. So fairly recently? 09:31:11A. Yes, sir. 09:31:12Q. And before that, you were 09:31:13	2 3	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16
2 3 4	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15	2 3 4	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16
2 3	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17	2 3 4 5	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19
2 3 4 5	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18	2 3 4	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23
2 3 4 5 6 7	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18	2 3 4 5 6	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23
2 3 4 5 6 7 8	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20	2 3 4 5 6 7	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23
2 3 4 5 6 7 8	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21	2 3 4 5 6 7 8	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25
2 3 4 5 6 7 8 9	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22	2 3 4 5 6 7 8	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27
2 3 4 5 6 7 8	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25	2 3 4 5 6 7 8 9	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33
2 3 4 5 6 7 8 9 10 11	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were senior manager of controlled substance compliance, correct? 09:31:15 A. Yes. 09:31:18 Q. Okay. And so was this considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27	2 3 4 5 6 7 8 9 10 11	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36
2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created 09:31:28	2 3 4 5 6 7 8 9 10 11 12 13	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37
2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created 09:31:28 for you? 09:31:30	2 3 4 5 6 7 8 9 10 11 12 13 14	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:38
2 3 4 5 6 7 8 9 10 11 12 13	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were senior manager of controlled substance op:31:15 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this op:31:18 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, op:31:22 09:31:25 A. No one. 09:31:27 Q. So was this position created op:31:30 09:31:30 A. Yes. 09:31:30	2 3 4 5 6 7 8 9 10 11 12 13 14	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:43
2 3 4 5 6 7 8 9 10 11 12 13 14 15	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created 09:31:28 for you? 09:31:30 A. Yes. 09:31:30 Q. Okay. And what were the 09:31:31	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:43 Q. And it indicates that you've 09:33:44
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created 09:31:28 for you? 09:31:30 A. Yes. 09:31:30 Q. Okay. And what were the 09:31:31 circumstances of creating this position? 09:31:34	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:43 Q. And it indicates that you've 09:33:44 been a member of the NADDI since 2013? 09:33:46
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were senior manager of controlled substance compliance, correct? 09:31:15 A. Yes. 09:31:18 Q. Okay. And so was this considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created op:31:30 A. Yes. 09:31:30 Q. Okay. And what were the op:31:31 circumstances of creating this position? 09:31:34 A. It was an evolution, if you op:31:36	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:43 Q. And it indicates that you've 09:33:44 been a member of the NADDI since 2013? 09:33:46 A. Yes. 09:33:50
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were senior manager of controlled substance compliance, correct? 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created 09:31:30 A. Yes. 09:31:30 Q. Okay. And what were the circumstances of creating this position? 09:31:31 circumstances of creating this position? 09:31:36 will, of my my existing job 09:31:39	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:43 Q. And it indicates that you've 09:33:44 been a member of the NADDI since 2013? 09:33:46 A. Yes. 09:33:50 Q. What is the NADDI? 09:33:51
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created 09:31:28 for you? 09:31:30 A. Yes. 09:31:30 Q. Okay. And what were the 09:31:31 circumstances of creating this position? 09:31:34 A. It was an evolution, if you 09:31:36 will, of my my existing job 09:31:43	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:38 A. Yes, I see it. Yes. 09:33:43 Q. And it indicates that you've 09:33:44 been a member of the NADDI since 2013? 09:33:46 A. Yes. 09:33:50 Q. What is the NADDI? 09:33:51 A. It's a group it's a 09:33:54
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created 09:31:28 for you? 09:31:30 A. Yes. 09:31:30 Q. Okay. And what were the 09:31:31 circumstances of creating this position? 09:31:34 A. It was an evolution, if you 09:31:36 will, of my my existing job 09:31:39 responsibilities that merited a different 09:31:43 title. 09:31:46	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:38 A. Yes, I see it. Yes. 09:33:43 Q. And it indicates that you've 09:33:44 been a member of the NADDI since 2013? 09:33:46 A. Yes. 09:33:50 Q. What is the NADDI? 09:33:51 A. It's a group it's a 09:33:54 consortium of industry, law enforcement 09:34:00
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created 09:31:30 A. Yes. 09:31:30 Q. Okay. And what were the 09:31:31 circumstances of creating this position? 09:31:34 A. It was an evolution, if you 09:31:36 will, of my my existing job 09:31:39 responsibilities that merited a different 09:31:43 title. 09:31:46 Q. Okay. And now that you're 09:31:46	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:43 Q. And it indicates that you've 09:33:44 been a member of the NADDI since 2013? 09:33:46 A. Yes. 09:33:50 Q. What is the NADDI? 09:33:51 A. It's a group it's a 09:33:54 consortium of industry, law enforcement 09:34:00 leaders that assemble to discuss the issues 09:34:05
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created 09:31:28 for you? 09:31:30 A. Yes. 09:31:30 A. Yes. 09:31:30 A. Yes. 09:31:30 A. Yes. 09:31:30 Q. Okay. And what were the 09:31:31 circumstances of creating this position? 09:31:34 A. It was an evolution, if you 09:31:36 will, of my my existing job 09:31:39 responsibilities that merited a different 09:31:43 title. 09:31:46 Q. Okay. And now that you're 09:31:46 director, do you have people that report to 09:31:55	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:38 A. Yes, I see it. Yes. 09:33:44 been a member of the NADDI since 2013? 09:33:44 been a member of the NADDI since 2013? 09:33:46 A. Yes. 09:33:50 Q. What is the NADDI? 09:33:51 A. It's a group it's a 09:33:54 consortium of industry, law enforcement 09:34:00 leaders that assemble to discuss the issues 09:34:05 around diversion. 09:34:10
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created 09:31:28 for you? 09:31:30 A. Yes. 09:31:30 Q. Okay. And what were the 09:31:31 circumstances of creating this position? 09:31:34 A. It was an evolution, if you 09:31:36 will, of my my existing job 09:31:39 responsibilities that merited a different title. 09:31:46 Q. Okay. And now that you're 09:31:46 director, do you have people that report to 09:31:55 you? 09:31:56	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:38 A. Yes, I see it. Yes. 09:33:43 Q. And it indicates that you've 09:33:44 been a member of the NADDI since 2013? 09:33:46 A. Yes. 09:33:50 Q. What is the NADDI? 09:33:51 A. It's a group it's a 09:33:54 consortium of industry, law enforcement 09:34:00 leaders that assemble to discuss the issues 09:34:10 Q. Okay. And diversion of 09:34:12
2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	Q. Okay. So fairly recently? 09:31:11 A. Yes, sir. 09:31:12 Q. And before that, you were 09:31:13 senior manager of controlled substance 09:31:15 compliance, correct? 09:31:17 A. Yes. 09:31:18 Q. Okay. And so was this 09:31:18 considered a promotion? 09:31:20 A. Yes. 09:31:21 Q. Okay. And who did you replace, 09:31:22 if at all? If anyone? 09:31:25 A. No one. 09:31:27 Q. So was this position created 09:31:28 for you? 09:31:30 A. Yes. 09:31:30 A. Yes. 09:31:30 A. Yes. 09:31:30 A. Yes. 09:31:30 Q. Okay. And what were the 09:31:31 circumstances of creating this position? 09:31:34 A. It was an evolution, if you 09:31:36 will, of my my existing job 09:31:39 responsibilities that merited a different 09:31:43 title. 09:31:46 Q. Okay. And now that you're 09:31:46 director, do you have people that report to 09:31:55	2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23	but this this appears to be a printout of 09:33:12 your LinkedIn profile; is that correct? 09:33:14 A. Yes. 09:33:16 Q. And does that appear to be an 09:33:16 accurate reflection or copy of your LinkedIn 09:33:19 profile? 09:33:23 A. Yes. 09:33:23 Q. And I don't want to spend too 09:33:23 much time on it, but I do want to ask you a 09:33:25 question about your involvement in the 09:33:27 National Association of Drug Diversion 09:33:33 Investigators. 09:33:36 Do you see that reference? I 09:33:37 believe that's on the next page. 09:33:38 A. Yes, I see it. Yes. 09:33:43 Q. And it indicates that you've 09:33:44 been a member of the NADDI since 2013? 09:33:46 A. Yes. 09:33:50 Q. What is the NADDI? 09:33:51 A. It's a group it's a 09:33:54 consortium of industry, law enforcement 09:34:00 leaders that assemble to discuss the issues 09:34:05 around diversion. 09:34:10